$1.79
4.28% yesterday
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

NRX Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
2 days ago
Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI , April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP), today announced signing of a term sheet with a global medical devic...
Neutral
PRNewsWire
5 days ago
Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Stephen Durand, founder of Dura, to serve as Director of Clinic Oper...
Neutral
PRNewsWire
12 days ago
Neurospa currently operates six interventional psychiatry clinics on Florida's Gulf Coast HOPE to acquire majority interest in Neurospa for a combination of cash and equity Neurospa clinics deliver a full range of interventional psychiatry services, including Ketamine, Spravato ® and Transcranial Magnetic Stimulation (TMS) to patients with severe depression and related conditions Acquisition to...
Neutral
Seeking Alpha
19 days ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Michael Abrams - Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Thomas Shrader - BTIG Vernon Bernardino - H.C.
Neutral
PRNewsWire
19 days ago
Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Suicidal Depression; planned filing of an NDA for Accelerated Approval under Breakthrough Designation and Priority Review of NRX-101 for the treatment of bipolar depression in people at risk of akathisia. Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accept...
Neutral
PRNewsWire
24 days ago
- Conference call to take place at 8:30am ET - WILMINGTON, Del. , March 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 17, 2025 via press release, which will be...
Neutral
PRNewsWire
about 2 months ago
• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10 th-12th WILMINGTON, Del. , Feb. 6, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE"), a medical and technology driven ...
Neutral
PRNewsWire
2 months ago
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics to treat severe depression and PTSD BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and related brokerage services Advisory to i...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today